Literature DB >> 28404761

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica Bauman, Lucian R Chirieac, Thomas A D'Amico, Malcolm M DeCamp, Thomas J Dilling, Michael Dobelbower, Robert C Doebele, Ramaswamy Govindan, Matthew A Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P Lackner, Michael Lanuti, Ticiana A Leal, Leah J Leisch, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Karen Reckamp, Gregory J Riely, Steven E Schild, Theresa A Shapiro, James Stevenson, Scott J Swanson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes.   

Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28404761     DOI： 10.6004/jnccn.2017.0050

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  429 in total

1.  Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Authors:  Barbara Melosky; Rosalyn Juergens; Vera Hirsh; Deanna McLeod; Natasha Leighl; Ming-Sound Tsao; Paul B Card; Quincy Chu
Journal:  Oncologist       Date:  2019-05-28

2.  Imaging Surveillance for Surgically Resected Stage I Non-Small Cell Lung Cancer: Is More Always Better?

Authors:  Melanie Subramanian; Jingxia Liu; Caprice Greenberg; Jessica Schumacher; George J Chang; Timothy L McMurry; Amanda B Francescatti; Tara R Semenkovich; Jessica L Hudson; Bryan F Meyers; Varun Puri; Benjamin D Kozower
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-24       Impact factor: 5.209

3.  Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung.

Authors:  Or Kalchiem-Dekel; Adina Paulk; Seth J Kligerman; Allen P Burke; Nirav G Shah; Renee K Dixon
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 4.  Managing the genomic revolution in cancer diagnostics.

Authors:  Doreen Nguyen; Christopher D Gocke
Journal:  Virchows Arch       Date:  2017-06-21       Impact factor: 4.064

5.  HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma.

Authors:  Honghong Jiang; Qiaofen Fu; Xin Song; Chunlei Ge; Ruilei Li; Zhen Li; Baozhen Zeng; Chunyan Li; Ying Wang; Yuanbo Xue; Rongcheng Luo; Weiyi Fang
Journal:  Oncol Lett       Date:  2019-09-05       Impact factor: 2.967

6.  Targeted therapy according to next generation sequencing-based panel sequencing.

Authors:  Motonobu Saito; Tomoyuki Momma; Koji Kono
Journal:  Fukushima J Med Sci       Date:  2018-04-07

7.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

8.  Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.

Authors:  Kai Wang; Xiao Qu; Shaorui Liu; Xudong Yang; Fenglong Bie; Yu Wang; Cuicui Huang; Jiajun Du
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-04       Impact factor: 4.553

9.  Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.

Authors:  Daniele Magnini; Leonello Fuso; Francesco Varone; Ettore D'Argento; Maurizio Martini; Antonietta Pecoriello; Vincenzo Di Noia; Damiano Arciuolo; Guido Fadda; Guido Rindi; Luca Richeldi
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

10.  Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.

Authors:  Koji Nishimoto; Masato Karayama; Naoki Inui; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Nao Inami; Shun Matsuura; Yusuke Kaida; Takashi Matsui; Kazuhiro Asada; Hiroyuki Matsuda; Masato Fujii; Mikio Toyoshima; Shiro Imokawa; Takafumi Suda
Journal:  Med Oncol       Date:  2018-06-16       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.